Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in IVF Cycles

Phase 4

Completed

• Conditions: Female Infertility
• Interventions: Drug: Clomifene Citrate

• Registration Number: NCT01791751
• Lead Sponsor: Fundació Privada Eugin

Brief Summary

The purpose of this study is to evaluate the effect on LH levels of the 5-day CC administration during luteal phase in oocyte donors, to investigate whether the CC corrects the suppressed LH levels in the luteal phase and whether it prolongs the luteal phase in the agonist triggered antagonist cycles.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-06
• Study First Submitted: 2012-11-12
• Status Verified: 2013-02
• Primary Completion: 2013-02
• Study Completion: 2013-02
• Study First Submitted QC: 2013-02-12
• Last Update Submitted: 2013-02-12
• Study First Posted: 2013-02-15
• Last Update Posted: 2013-02-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 10

Inclusion Criteria

• Oocyte donors
• 18-35 years old
• BMI 18-29 Kg/m2
• Normal basal hormonal levels
• No contraceptive pill

Exclusion Criteria

• Polycystic ovarian syndrome (PCOS)
• Previous participation in the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Clomifene Citrate	Clomifene Citrate	Clomifene Citrate 50 mg

Primary Outcome Measures

Name	Time	Method
LH Levels (IU)	Luteal phase (up to 2 weeks)

Secondary Outcome Measures

Name	Time	Method
Endometrial development (Noyes criteria)	Luteal phase (1 day)

Trial Locations

Locations (1)

Clínica EUGIN; 🇪🇸 Barcelona, Spain